MSN Pharmaceuticals has requested the Federal Circuit to permit the launch of its generic version of the heart medication Entresto, originally developed by Novartis, amid ongoing litigation. The legal proceedings revolve around a recently expired patent, and at present, a temporary injunction prevents MSN from proceeding with its product launch. This request highlights the high stakes involved in the generic drug industry, where patent expirations often lead to conflicts between brand-name pharmaceutical companies and generic manufacturers over market entry.
For further details on this legal development, visit the original article on Law360.